Our study showed that LY2510924 effectively disrupted the CXCL12/CXCR4 axis and reversed stroma-mediated extrinsic resistance to FLT3 inhibitors in FLT3-ITD-AML, mainly through the downregulation of stroma-induced MAPK activation. The gene discussed is CXCL12; the disease is acute myeloid leukemia.